Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
Loading...
Contact
Check for full-text access
Issue Date
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background: Risankizumab (RZB), a monoclonal antibody neutralizing interleukin (IL)-23p19, was evaluated for efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC) in the phase 3 trial, INSPIRE (NCT03398148).
Description
Citation
Publisher
License
Journal
The American Journal of Gastroenterology